Abstract
Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer.
Highlights
The concurrent systematic reviews recently published in Frontiers in Oncology by Zhize Wang et al [1] and Jiaxin Wang et al [2] provide a very similar report on the prognostic value of the androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer
Other included results were the prostate specific antigen (PSA) response rate, PFS, or OS after novel hormonal therapy (NHT) or chemotherapy; 3) Results reported from clinical trials including RCTs and nonrandomized studies; January 1974 to September 2019
1) Studies reporting on the association between AR-V7 status at baseline and timeto-events outcomes for mCRPC patients treated with ARSis or chemotherapy, including PSA response, clinical and/or radiographic PFS or OS; 2) Odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were reported directly or could be calculated; 3) Clinical studies performed with adults and were published in English
Summary
The concurrent systematic reviews recently published in Frontiers in Oncology by Zhize Wang et al [1] and Jiaxin Wang et al [2] provide a very similar report on the prognostic value of the androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer. 1) Studies reporting on CRPC and AR-V7; 2) Results expressed as an 86% positive rate in AR-V7 before and after treatment in CRPC. Other included results were the PSA response rate, PFS, or OS after NHT or chemotherapy; 3) Results reported from clinical trials including RCTs and nonrandomized studies; January 1974 to September 2019
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
